An Act Regarding Advertising Manufacturers to H.P. by Drug Amend the amendment by inserting after the title the following: Amend the bill by striking out the title and substituting the following: , An Act Regarding Advertising by Drug Manufacturers and Disclosure of Clinical Trials' , Further amend the amendment in the first paragraph after the title in the first line (page 1, line 22 in amendment) by striking out the following: Amend" and inserting in its place the following: Further amend Further amend the amendment in section 1 in that part designated "§2100-A." in subsection 3 by striking out all of the first indented paragraph (page 2, lines 27 to 36 in amendment) and inserting in its place the following: , 3. Disclosure of clinical trials of prescription drugs. Beginning October 15, 2005, a manufacturer or labeler of prescription drugs that is required to report marketing costs for prescription drugs pursuant to section 2698-; shall post. with .r..egard to those Prescription drugs, on the publicly accessible Internet website of the federal National Institutes of Health or its successor agency or another publicly accessible website the following information concerning any clinical trial that the manufacturer conducted or sponsored on or after October 15, 2002: Page 1-LR0487(5) HOUSE AMENDMENT
Maine Legislature, Session 122, LD 1618
Committee Amendment CA_A-HA_A_H675 (House)

HOUSE 
AMENDMENT "A" to COMMITTEE 
AMENDMENT 
"A" 
1141, 
L.D. 
1618, Bill, 
"An Act Regarding Advertising 
Manufacturers" 
to H.P. 
by Drug 
Amend 
the 
amendment 
by 
inserting after 
the 
title 
the 
following: 
'Amend the bill by striking out the title and substituting 
the following: 
, An 
Act 
Regarding 
Advertising 
by 
Drug 
Manufacturers 
and 
Disclosure of Clinical Trials' , 
Further amend the amendment in the first paragraph after the 
title in the first line 
(page 1, 
line 22 
in amendment) 
by 
striking out the following: 
"Amend" and inserting in its place 
the following: 
'Further amend' 
Further 
amend 
the 
amendment 
in section 1 
in that part 
designated "§2100-A." in subsection 3 by striking out all of the 
first indented paragraph (page 2, lines 27 to 36 in amendment) 
and inserting in its place the following: 
, 3. 
Disclosure of clinical trials of prescription drugs. 
Beginning 
October 
15, 
2005, 
a 
manufacturer 
or 
labeler 
of 
prescription drugs that is required to report marketing costs for 
prescription drugs pursuant to section 2698-; shall post. with 
.r..egard to those Prescription drugs, on the publicly accessible 
Internet website of the federal 
National Institutes of Health or 
its successor agency or another publicly accessible website the 
following information concerning any clinical trial that the 
manufacturer conducted or sponsored on or after October 15, 2002:' 
HOUSE AMENDMENT 
HOUSE 
AMENDMENT 
L.D. 1618 
.. A .. 
to COMMITTEE 
AMENDMENT 
"A" to H. P . 
SUMMARY 
1141, 
This 
amendment 
removes 
the 
provision 
that 
requires 
a 
manufacturer 
of 
prescription 
drugs 
to 
disclose 
certain 
information 
regarding 
clinical 
trials 
of 
prescription 
drugs 
before regulated advertisements for those prescription drugs may 
be 
presented 
and 
replaces 
it with 
a 
requirement 
that 
a 
manufacturer or labeler of prescription drugs that is required to 
report marketing costs for prescription drugs pursuant to the 
Maine Revised Statutes, Title 22, section 2698-A disclose certain 
information regarding clinical trials of prescription drugs. 
SPONSORED BY: 
TOWN: 
Augusta 
HOUSE AMENDMENT